《大行》匯豐研究升東方證券(03958.HK)目標價至5.6元 維持「持有」評級
匯豐研究發表報告指,交易量復甦和產品多元化帶動東方證券(03958.HK)收入增加,上調2025至2027年淨利預測4%至23%。維持該股H股「持有」評級,目標價由4.2元升至5.6元。
匯豐研究將東方證券2025至2027年經紀收入預測上調7.2%至19.3%,以反映近期交易量按年回升,經紀佣金收入增加;將2025至2027年資產管理收入預估下調4.2%至4.6%,以反映投資人在目前的宏觀環境下,對於選擇風險偏好較高的經紀公司作為資產配置管道的謹慎態度,使得資產管理收入低於預期;將2025至2027年自營投資收入預估各調高2%,以反映近期股市表現強勁,可能提振公司的投資收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.